Economic evaluation of strategies for managing women with equivocal cytological results in Brazil

International Journal of Cancer

Volumn 129, Issue 3, 2011, Pages 671-679

  Vanni, Tazio ^a   Legood, Rosa ^a   Franco, Eduardo L ^b   Villa, Luisa L ^c   Luz, Paula Mendes ^d   Schwartsmann, Gilberto ^e  

^a LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE   (United Kingdom)

^b MCGILL UNIVERSITY   (Canada)

^c HOSPITAL ALEMÃO OSWALDO CRUZ   (Brazil)

^d INSTITUTO EVANDRO CHAGAS   (Brazil)

^e FEDERAL UNIVERSITY OF RIO GRANDE DO SUL   (Brazil)

Author keywords

atypical squamous cells of unknown significance; cervical cancer screening; cost effectiveness; economic evaluation

Indexed keywords

VIRUS DNA;

ARTICLE; ATYPICAL SQUAMOUS CELLS OF UNDETERMINED SIGNIFICANCE; BRAZIL; COHORT ANALYSIS; COLPOSCOPY; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; COST PER YEARS OF LIFE SAVED; DNA DETERMINATION; ECONOMIC EVALUATION; GYNECOLOGIC DISEASE; HEALTH CARE COST; INCOME; MARKOV MODEL; MATHEMATICAL MODEL; OUTCOME ASSESSMENT; PAPANICOLAOU TEST; PATIENT CARE; PATIENT REFERRAL; PRIORITY JOURNAL; SOCIAL STATUS; TREATMENT PLANNING; VIRUS DETECTION; WART VIRUS;

ADULT; COLPOSCOPY; COST-BENEFIT ANALYSIS; EARLY DETECTION OF CANCER; FEMALE; HUMANS; MARKOV CHAINS; MIDDLE AGED; PAPILLOMAVIRUS INFECTIONS; SENSITIVITY AND SPECIFICITY; UTERINE CERVICAL DYSPLASIA; UTERINE CERVICAL NEOPLASMS; VAGINAL SMEARS;

EID: 79958069108     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.25708     Document Type: Article

References (50)

1. Ferlay JBF, Pisani P, Parkin DM, Bray F, GLOBOCAN 2000: cancer incidence, mortality and prevalence worldwide version 1.0, 2001.
2. Yang BH, Bray FI, Parkin DM, Sellors JW, Zhang Z-F,. Cervical cancer as a priority for prevention in different world regions: an evaluation using years of life lost. Int J Cancer 2004; 109: 418-24. (Pubitemid 38252771)
3. Franco EL, Tsu V, Herrero R, Lazcano-Ponce E, Hildesheim A, Muñoz N, Murillo R, Sánchez GI, Andrus JK,. Integration of human papillomavirus vaccination and cervical cancer screening in Latin America and the Caribbean. Vaccine 2008; 26: L88-95.
4. Estimativa 2010: Incidencia de Cancer no Brasil. INCA. Rio de Janeiro, 2009. Available at:. Accessed on the 16th July 2010.
5. Nomenclatura Brasileira para laudos cervicais e condutas preconizadas. Instituto Nacional do Cancer (INCA), 2nd edn. Rio de Janeiro, 2006. Available at:. Accessed on 16th July 2010.
6. Andrus JK, Lewis MJ, Goldie SJ, García PJ, Winkler JL, Ruiz-Matus C, de Quadros CA,. Human papillomavirus vaccine policy and delivery in Latin America and the Caribbean. Vaccine 2008; 26: L80-7.
7. Kim JJ, Wright TC, Goldie SJ,. Cost-effectiveness of alternative triage strategies for atypical squamous cells of undetermined significance. JAMA 2002; 287: 2382-90. (Pubitemid 34493201)
8. Legood R, Gray A, Wolstenholme J, Moss S,. Lifetime effects, costs, and cost effectiveness of testing for human papillomavirus to manage low grade cytological abnormalities: results of the NHS pilot studies.[see comment]. BMJ 2006; 332: 79-85.
9. Berkhof J, Bruijne MCD, Zielinski GD, Bulkmans NWJ, Rozendaal L, Snijders PJF, Verheijen RHM, Meijer CJLM,. Evaluation of cervical screening strategies with adjunct high-risk human papillomavirus testing for women with borderline or mild dyskaryosis. Int J Cancer 2006; 118: 1759-68. (Pubitemid 43376440)
10. Kinney WK, Manos MM, Hurley LB, Ransley JE,. Where's the high-grade cervical neoplasia? The importance of minimally abnormal Papanicolaou diagnoses. Obstet Gynecol 1998; 91: 973-6. (Pubitemid 28246934)
11. Kim JJ, Kuntz KM, Stout NK, Mahmud S, Villa LL, Franco EL, Goldie SJ,. Multiparameter calibration of a natural history model of cervical cancer. Am J Epidemiol 2007; 166: 137-50. (Pubitemid 47227293)
12. Munoz N, Bosch FX, de Sanjose S, Herrero R, Castellsague X, Shah KV, Snijders PJF, Meijer CJLM, the International Agency for Research on Cancer Multicenter Cervical Cancer Study G. Epidemiologic classification of human papillomavirus types associated with cervical cancer. N Engl J Med 2003; 348: 518-27. (Pubitemid 36159887)
13. Trottier H, Mahmud S, Prado JCM, Sobrinho JS, Costa MC, Rohan TE, Villa LL, Franco EL,. Type-specific duration of human papillomavirus infection: implications for human papillomavirus screening and vaccination. J Infect Dis 2008; 197: 1436-47. (Pubitemid 351706468)
14. Franco E, Villa L, Rohan T, Ferenczy A, Petzl-Erler M, Matlashewski G,. Design and methods of the Ludwig-McGill longitudinal study of the natural history of human papillomavirus infection and cervical neoplasia in Brazil. Revista Panamericana de Salud Pública 1999; 6: 223-33. (Pubitemid 29523611)
15. Franco EL, Villa LL, Sobrinho JP, Prado JM, Rousseau M-C, Desy M, Rohan TE,. Epidemiology of acquisition and clearance of cervical human papillomavirus infection in women from a high-risk area for cervical cancer. J Infect Dis 1999; 180: 1415-23. (Pubitemid 29506440)
16. Molano M, Posso H, Weiderpass E, van den Brule AJC, Ronderos M, Franceschi S, Meijer CJLM, Arslan A, Munoz N,. Prevalence and determinants of HPV infection among Colombian women with normal cytology. Br J Cancer 2002; 87: 324-33.
17. Munoz N, Mendez F, Posso H, Molano M, van den Brule AJC, Ronderos M, Meijer C, Munoz A,. Incidence, duration, and determinants of cervical human papillomavirus infection in a cohort of Colombian women with normal cytological results. J Infect Dis 2004; 190: 2077-87. (Pubitemid 39636354)
18. Pecorelli S NH, Hacker NF,. Staging classification and clinical practice guidelines for gynaecological cancers. Available at:. Accessed on 16th October 2010.
19. Myers ER, McCrory DC, Nanda K, Bastian L, Matchar DB,. Mathematical model for the natural history of human papillomavirus infection and cervical carcinogenesis. Am J Epidemiol 2000; 151: 1158-71. (Pubitemid 30451948)
20. Instituto Brasileiro de Geografia e Estatistica, Brazilian Institute of Geography and Statistics (IBGE). Available at:. Accessed on 16th October 2010.
21. Kim JJ, Wright TC, Goldie SJ,. Cost-effectiveness of human papillomavirus DNA testing in the United Kingdom, The Netherlands, France, and Italy. J Natl Cancer Inst 2005; 97: 888-95. (Pubitemid 41417940)
22. Van de Velde N, Brisson M, Boily M-C,. Modeling human papillomavirus vaccine effectiveness: quantifying the impact of parameter uncertainty. Am J Epidemiol 2007; 165: 762-75. (Pubitemid 46434599)
23. Goldhaber-Fiebert J, Stout N, Ortendahl J, Kuntz K, Goldie S, Salomon J,. Modeling human papillomavirus and cervical cancer in the United States for analyses of screening and vaccination. Popul Health Metr 2007; 5: 11.
24. Nanda K, McCrory DC, Myers ER, Bastian LA, Hasselblad V, Hickey JD, Matchar DB,. Accuracy of the Papanicolaou test in screening for and follow-up of cervical cytologic abnormalities: a systematic review. Ann Intern Med 2000; 132: 810-9. (Pubitemid 30317797)
25. Dickson RJ,. Management of carcinoma of the cervix. Practitioner 1980; 224: 899-904. (Pubitemid 10023366)
26. Karnon J, Goyder E, Tappenden P, McPhie S, Towers I, Brazier J, Madan J,. A review and critique of modelling in prioritising and designing screening programmes. Health Technol Assess 2007; 11: iii-iv, ix-xi, 1- 145.
27. Rao SS,. Engineering optimization: theory and practice, 4th edn. Chichester, England: Wiley, 2009.
28. Schlecht NF, Platt RW, Duarte-Franco E, Costa MC, Sobrinho JP, Prado JC, Ferenczy A, Rohan TE, Villa LL, Franco EL,. Human papillomavirus infection and time to progression and regression of cervical intraepithelial neoplasia. J Natl Cancer Inst 2003; 95: 1336-43. (Pubitemid 37160867)
29. Goldie SJ, Kim JJ, Kobus K, Goldhaber-Fiebert JD, Salomon J, O'Shea MKH, Xavier Bosch F, de Sanjosé S, Franco EL,. Cost-effectiveness of HPV 16, 18 vaccination in Brazil. Vaccine 2007; 25: 6257-70. (Pubitemid 47088030)
30. Clifford GM, Rana RK, Franceschi S, Smith JS, Gough G, Pimenta JM,. Human papillomavirus genotype distribution in low-grade cervical lesions: comparison by geographic region and with cervical cancer. Cancer Epidemiol Biomarkers Prev 2005; 14: 1157-64. (Pubitemid 40656461)
31. Woodman CBJ, Collins S, Winter H, Bailey A, Ellis J, Prior P, Yates M, Rollason TP, Young LS,. Natural history of cervical human papillomavirus infection in young women: a longitudinal cohort study. Lancet 2001; 357: 1831-6. (Pubitemid 32539115)
32. Ho GY, Burk RD, Klein S, Kadish AS, Chang CJ, Palan P, Basu J, Tachezy R, Lewis R, Romney S,. Persistent genital human papillomavirus infection as a risk factor for persistent cervical dysplasia. J Natl Cancer Inst 1995; 87: 1365-71.
33. Murillo R, Almonte M, Pereira A, Ferrer E, Gamboa OA, Jerónimo J, Lazcano-Ponce E,. Cervical cancer screening programs in Latin America and the Caribbean. Vaccine 2008; 26: L37-48.
34. Arbyn M, Buntinx F, Ranst MV, Paraskevaidis E, Martin-Hirsch P, Dillner J,. Virologic versus cytologic triage of women with equivocal pap smears: a meta-analysis of the accuracy to detect high-grade intraepithelial neoplasia. J Natl Cancer Inst 2004; 96: 280-93. (Pubitemid 38256273)
35. Mitchell MF, Schottenfeld D, Tortolero-Luna G, Cantor SB, Richards-Kortum R,. Colposcopy for the diagnosis of squamous intraepithelial lesions: a meta-analysis. Obstet Gynecol 1998; 91: 626-31. (Pubitemid 28153058)
36. Methodological guidelines for appraisals on health technology assessment for the Ministry of Health of Brazil. Brasilia, 2007.
37. Classificacao Brasileira Hierarquizada de Procedimentos Medicos, 5th edn., 2008. Available at:. Accessed on 16th October 2010.
38. Central Intelligence Agency-The World Factbook, vol. 2009. Available at:. Accessed on 16th October 2010.
39. Caetano R, Vianna CMdM, Thuler LCS, Girianelli VR,. Custo-efetividade no diagnóstico precoce do câncer de colo uterino no Brasil. Physis: Revista de Saúde Coletiva 2006; 16: 99-118.
40. Drummond MF SM, Torrance GW, et al. Methods for the economic evaluation of health care programmes, 3rd ed. Oxford University Press, 2005.
41. WHO. Macroeconomics and health: investing in health for economic development: report of the commission on macroeconomics and health. Geneva: World Health Organization, 2001.
42. Goldie SJ, Diaz M, Kim S-Y, Levin CE, Van Minh H, Kim JJ,. Mathematical models of cervical cancer prevention in the Asia Pacific region. Vaccine 2008; 26: M17-29.
43. Goldie SJ, Gaffikin L, Goldhaber-Fiebert JD, Gordillo-Tobar A, Levin C, Mahe C, Wright TC,. Cost-effectiveness of cervical-cancer screening in five developing countries. N Engl J Med 2005; 353: 2158-68. (Pubitemid 41653107)
44. International Monetary Fund-The World Economic Outlook Database, vol. 2010. Available at:. Accessed on 16th October 2010.
45. Briggs A CK, Sculpher M,. Decision modelling for health economic evaluation, 1st edn. Oxford University Press, 2007.
46. Drummond MF, McGuire A,. Economic evaluation in health care: merging theory with practice, 1st edn. Oxford University Press, 2001.
47. Jit M, Choi YH, Edmunds WJ,. Economic evaluation of human papillomavirus vaccination in the United Kingdom. BMJ 2008; 337: a769.
48. Goldie SJ, Goldhaber-Fiebert JD, Garnett GP,. Chapter 18: public health policy for cervical cancer prevention: the role of decision science, economic evaluation, and mathematical modeling. Vaccine 2006; 24: S155-63. (Pubitemid 44293024)
49. Franco EL, Cuzick J,. Cervical cancer screening following prophylactic human papillomavirus vaccination. Vaccine 2008; 26: A16-23. (Pubitemid 351312311)
50. Edmunds WJ, Medley GF, Nokes DJ,. Evaluating the cost-effectiveness of vaccination programmes: a dynamic perspective. Stat Med 1999; 18: 3263-82.